HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hauser, R. A. Articles by Zesiewicz, T. A. Search for Related Content PubMed PubMed Citation Articles by Hauser, R. A. Articles by Zesiewicz, T. A.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Clinical trials aimed at detecting neuroprotection in Parkinson’s disease

From the Departments of Neurology (Drs. Hauser and Zesiewicz) and Pharmacology and Experimental Therapeutics (Dr. Hauser), University of South Florida and Tampa General Healthcare, Tampa, Florida.

Address correspondence and reprint requests to Dr. Robert A. Hauser, Parkinson’s Disease and Movement Disorders Center, NPF Center of Excellence, 4 Columbia Drive, Suite 410, Tampa, FL 33606; e-mail: rhauser{at}hsc.usf.edu

Potential neuroprotective therapies for Parkinson’s disease (PD) are being identified in the laboratory and evaluated in the clinic in an effort to improve long-term outcomes for patients. Several clinical trial designs and methodologies have been used in an attempt to identify neuroprotective effects of medications. Such studies have evaluated (a) time to onset of a clinical milestone of disease progression, (b) progression of clinical symptoms from untreated baseline to an untreated endpoint obtained after wash-out of study intervention, (c) progression of clinical symptoms in early PD, (d) change in imaging markers over time, and (e) a combination of clinical (wash-out) and imaging markers. None of these approaches has yet provided a definitive means to evaluate neuroprotection. Clinical outcomes can be confounded by symptomatic effects of treatments, and imaging markers can be affected by pharmacologic or pharmodynamic changes resulting from treatment. Better methods of assessing putative neuroprotection in PD are needed.

Publication of this supplement was supported by an educational grant from Teva Neuroscience and Eisai, Inc.

Disclosure: RAH has received the following from the sponsor of this supplement: an honorarium for his participation in this project, personal honoraria and grant support during his career. TAZ has received personal honoraria from the sponsor during her professional career.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology.